[ET Net News Agency, 27 January 2021] Macquarie Research initiated coverage on JD
Health (JDH) (06618) with an "outperform" rating and target price of HK$193.
The research house sees higher growth visibility for the e-commerce companies versus
policy-dependent online medical services. JDH, as an industry leader, has ample growth
drivers to leverage, improving profitability, more affluent customers, and an impressive
management team.
Macquarie forecasted JDH's overall revenue to grow at a 56% CAGR during 2020-23, while
it estimated the overall adj OPM will improve from 4.6% in 2020 to 8.7% in 2023,
reflecting e-commerce core operating profit growth at a 99% CAGR in 2020-23, primarily
attributable to economies of scale. (KL)